Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs zoledronic acid for bone metastases in advanced breast cancer
jRCT2080220875Phase 3
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of denosumab in breast cancer and bone metastases (2 arms), sponsored by Daiichi Sankyo Co., Ltd.
02
Drugs
denosumab
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on jRCT2080220875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220875.